The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
No linked publications found in PubMed
Inclusion Criteria: * patients with cystic fibrosis older than 8 years * with chronic Pseudomonas aeruginosa infection of the respiratory tract * with at least 2 courses of IV antibiotic in the year before enrolment * at the time of a pulmonary exacerbation Exclusion Criteria: * allergy to ceftazidime or tobramycin * bronchial colonization with Burkholderia cepacia * renal impairment * history of lung transplantation